I
nhaled corticosteroids (ICS) are considered the most effective anti-inflammatory treatments for all severities of persistent asthma. [1] [2] [3] [4] National and international guidelines advocate the use of ICS for reducing asthma symptoms and the risk of exacerbations in children aged 5-11 years with persistent asthma. [1] [2] [3] Despite effective treatment being available, however, many children with asthma remain uncontrolled. The Global Initiative for Asthma guidelines define uncontrolled asthma as having ≥3 of the following in the previous 4 weeks: daytime asthma symptoms >2 times per week; any night waking due to asthma; the need for reliever for symptoms >2 times per week; or any activity limitation due to asthma. 2 Low adherence has been proposed as a potential contributing factor to uncontrolled asthma in children. 5, 6 In addition, adherence to medications including ICS primarily has been shown to decline as the number of doses per day increases, 7, 8 including in children with asthma. 9 
AUC0-24
Area under the plasma-concentration curve over 0- 24 Fluticasone furoate (FF), delivered via the ELLIPTA inhaler (GlaxoSmithKline, Hertfordshire, United Kingdom), is a novel ICS that has been approved as a once-daily treatment of asthma in adult and adolescent patients in the US. 10 The purpose of this study was to evaluate the dose-response, efficacy, and safety of 3 doses of FF (25 mg, 50 mg, and 100 mg) administered once daily in the evening during a 12-week treatment period to children aged 5-11 years with inadequately controlled asthma. Fluticasone propionate (FP) 100 mg was used as an active comparator.
Methods
This was a Phase IIb, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, placebo-and active-controlled study (with rescue medication) in children aged 5-11 years with inadequately controlled asthma (ClinicalTrials.gov: NCT01563029 [106855] ). The study consisted of a 4-week run-in period, 12-week treatment period, and 1-week follow-up period. During the run-in, children continued taking their current asthma medication. All children were provided with albuterol/salbutamol as needed for the relief of asthma symptoms.
The original primary endpoint was change from baseline in predose evening peak expiratory flow (PEF) at week 12, with missing data for this endpoint assessment imputed by the use of last observation carried forward (LOCF). This was changed to the change from baseline in daily predose morning PEF averaged over weeks [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] to use all available PEF data during the treatment period, thereby requiring no imputation of missing data. The endpoint also was changed for consistency with the analysis of PEF in the adult FF/vilanterol (VI) program. 11, 12 This change of endpoint was made at the time of writing the reporting and analysis plan, before we unblinded the database, and was approved by the European Medicines Agency Paediatric Committee.
Eligible children were aged 5-11 years, had symptoms of asthma at least 6 months before screening, and had been receiving short-acting beta2-agonist (SABA) alone, SABA with a leukotriene modifying agent, or SABA with low-dose ICS (≤250 mg FP) for ≥4 weeks before screening. Children also had prebronchodilator PEF of 60%-90% of their best postbronchodilator value, and, for those able to perform the maneuver, demonstrated a ≥12% reversibility of forced expiratory volume in 1 second (FEV1) within~10-40 minutes following 2-4 inhalations of albuterol/salbutamol. Excluded children had a history of life-threatening asthma; change in asthma medication within 4 weeks of screening; an asthma exacerbation (defined as a deterioration of asthma either requiring the use of systemic corticosteroids for ≥3 days, or a depot corticosteroid injection ≤3 months before screening, or hospitalization or emergency department visit for asthma ≤6 months before screening); concurrent respiratory disease; or any other clinically significant medical condition.
At the end of the run-in period, children eligible for randomization had a prebronchodilator PEF of 60%-90% of their best postbronchodilator value; symptoms of asthma (a score of ≥1 on the daytime or nighttime asthma symptom scores reported on the eDiary); and/or daily use of albuterol/salbutamol on ≥3 of the last 7 consecutive days of the run-in period. In addition, eligible children complied with the run-in medication on ≥4 of the last 7 consecutive days of the run-in period and completed all questions on the eDiary on ≥4 of the 7 days during the screening period. Children excluded from randomization had a change in asthma medication since screening; an asthma exacerbation between screening and randomization; or concurrent respiratory disease or any other clinically significant medical condition.
The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and was approved by the relevant ethics committee or institutional review board at each investigational center. Written informed consent was obtained from 2 parents/legal guardians. If applicable, the child had to be able and willing to give assent to take part in the study according to the local requirements. The investigator was accountable for determining a child's capacity to assent.
Treatment and Assessments
Children were assigned randomly 1:1:1:1:1 to receive either placebo via the ELLIPTA inhaler, FP 100 mg twice daily via the DISKUS inhaler (GlaxoSmithKline), or FF 25 mg, FF 50 mg, or FF 100 mg each once daily in the evening via the ELLIPTA inhaler. In addition, each received placebo twice daily via the DISKUS inhaler, except for children in the FP 100 mg group, who received placebo once daily via the ELLIPTA inhaler. Randomization was stratified by previous ICS therapy. Morning and evening PEF were measured daily by the use of an eDiary with a peak flow meter. FEV1 was measured in a subset of children in the evening at clinic visits via an electronic spirometer, at screening, randomization, and weeks 2, 4, 8, and 12.
Endpoints
The primary endpoint was the mean change from baseline in daily predose morning PEF averaged over weeks 1-12. Secondary efficacy endpoints were change from baseline in: (1) evening study visit trough FEV1 at the end of the treatment period (using LOCF for imputation of missing postbaseline FEV1 values); (2) percentage of rescue-free and symptomfree days averaged over the treatment period; (3) daily predose evening PEF averaged during the treatment period; (4) morning and evening PEF over the last 7 days of the treatment period; and (5) number of withdrawals due to lack of efficacy during the treatment period. Withdrawal because of a lack of efficacy was defined as reaching the PEF stability limit, use of albuterol/salbutamol, experiencing a clinical asthma exacerbation, or worsening of asthma (defined as requiring treatment other than study medication or use of rescue albuterol/ salbutamol, including nebulization). Other endpoints included change from baseline in the childhood Asthma Control Test (cACT) score at week 12 and change from baseline in the Standardised Paediatric Asthma Quality of Life Questionnaire, or PAQLQ(S), 13 score at week 12. Pharmacokinetics (PK) blood samples were collected predose and 20-40 minutes postdose at week 12. Plasma samples were Volume 178 • November 2016 247 analyzed for FF by mass spectrometry. The lower limit of quantification was 10 pg/mL. The PK variables, maximum concentration, and area under the plasma-concentration curve over 0-24 hours (AUC0−24) were assessed with PK analysis of the plasma concentration-time data.
Safety and tolerability endpoints included: (1) the incidence of adverse events (AEs) over weeks 1-12; (2) 24-hour urinary cortisol (UC) excretion at baseline and week 12; (3) laboratory assessments at screening and week 12 or early withdrawal; (4) incidence of severe asthma exacerbations throughout the treatment period; and (5) vital signs at randomization and at weeks 2, 4, 8, and 12, or early withdrawal.
Statistical Analysis
With 575 children (115 children per treatment group) the study had 90% power assuming a difference of 12 L/min in morning PEF in the gatekeeper comparison between the average of the greater 2 FF doses (FF 100 mg and FF 50 mg) and placebo, an SD of 28 L/min, and significance declared at the 2-sided 5% level. The study also had 90% power assuming a 12 L/min difference in morning PEF in the comparisons between any active dose and placebo. To account for multiplicity across treatment comparisons for the primary endpoint, comparisons of each FF dose with placebo followed a step-down closed testing procedure.
Provided the test of the average of the 2 greater FF doses vs placebo was statistically significant, inference could be made on comparisons of FF 100 mg vs placebo and FF 50 mg vs placebo. Similarly, if both of these comparisons were statistically significant, inference could then be made on the comparison of FF 25 mg vs placebo with no further multiplicity adjustment. For all efficacy and safety endpoints, the FP 100 mg group was compared with placebo to provide a positive control of relative efficacy.
The intent-to-treat (ITT) population comprised all children randomized to treatment who received ≥1 study medication. The per-protocol (PP) population comprised all children in the ITT population without any full protocol deviations. The UC population consisted of children whose urine samples had no confounding factors that would have affected the interpretation of UC results. Finally, the PK population consisted of children in the ITT population for whom a PK sample was analyzed for FF. The population PK analysis included concentration-time data from the current study combined with data from 2 previous studies. 14, 15 The primary efficacy endpoint was analyzed with an analysis of covariance model, allowing for the effects due to baseline morning PEF, region, sex, actual prescreening ICS use, age, and treatment group on the ITT and PP populations. Because missing data were not imputed in this analysis, 5 sensitivity analyses examined the impact of missing data: 1 mixed modeling repeated measures (MMRM) analysis and 4 multiple imputation sensitivity analyses. The MMRM analysis accounted for effects due to baseline morning PEF, region, sex, age, week, and treatment group, including week-by-treatment and weekby-baseline interaction terms. The other 4 imputation sensitivity analyses used a Missing at Random approach, a Copy Increment from Reference approach, a Jump to Reference approach, and a Copy Reference approach. All sensitivity analyses examined an average treatment effect across the treatment period. Three further supporting analyses were performed on the primary endpoint: dose-response models, Bayesian analyses with noninformative priors, and a MMRM model presenting estimates from each week.
Statistical analyses for secondary endpoints were performed with ANCOVA models with effects due to baseline, region, sex, age, and treatment group. For the secondary endpoint of evening trough FEV1, an MMRM, and a Bayesian analysis also were performed. The MMRM analysis was as per the primary endpoint. The Bayesian analysis examined the posterior probability distribution of the treatment differences of each active treatment against placebo. For trough FEV1 and morning and evening PEF at the endpoint, missing data were imputed by use of the LOCF. Programming was performed with SAS, version 9.1.3 (SAS Institute, Inc, Cary, North Carolina) or later. Evaluation of percent predicted FEV1 values at baseline were not prespecified in the protocol and are reported as post hoc analyses.
Results
A total of 1540 children were screened, 596 children were randomized with 593 (99.5%) children included in the ITT population (Figure 1 ; available at www.jpeds.com). The study period, from the first screening to the last visit, was from March 2012 to September 2014. Demographics were generally similar between treatment groups ( Table I) . There was a lower proportion of children aged 5-7 years in the FF 50 mg treatment group (26%) compared with the other treatment groups (41%-47%). A total of 172 (29%) children withdrew during the study (Figure 1) , primarily due to lack of efficacy; the latter was greater in the placebo group (35%) than in the FF groups (14%-19%) and the FP group (16%).
Primary Endpoint
The adjusted treatment differences in the mean change from baseline in daily predose morning PEF vs placebo were 18.6 L/min, 19.5 L/min, and 12.5 L/min for the FF 25 mg, FF 50 mg, and FF 100 mg groups, respectively (Table II and Figure 2; Figure 2 available at www.jpeds.com). In accordance with the step-down closed testing procedure, all treatment differences vs placebo were statistically significant (P < .001; Table II ). The analysis of the primary endpoint using the PP population plus all sensitivity and supporting analyses using the ITT population supported the findings of the primary analysis. There was no apparent FF dose-ordering. The adjusted treatment difference in the mean change from baseline in morning PEF for FP 100 mg vs placebo also was statistically significant (14.0 L/min; P < .001; Table II) . When stratified by prescreening ICS use, mean changes from baseline in morning PEF were greater for the active treatment groups than placebo for children with prescreening ICS use and without (Table II) . Changes were similar regardless of prescreening ICS use.
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Secondary Endpoints
The analysis of change from baseline in trough FEV1 at week 12 (LOCF) included 508 children (86%) in the ITT population who provided technically acceptable FEV1 data 16 both at baseline and at least 1 postbaseline visit. There was a statistically significant adjusted treatment difference in the change from baseline in trough FEV1 at week 12 (LOCF) for the FF 25 mg group compared with placebo (126 mL, P < .001) but not for the other treatment comparisons ( Table II) . The results of the MMRM analysis supported the findings of the ITT analysis; however, in a post hoc analysis including only children with acceptable FEV1 measurements, all treatment groups demonstrated numerically greater changes from baseline vs placebo (Table III ; available at www.jpeds.com). A further post hoc analysis of FEV1 data by age subgroup was performed because of statistically significant interactions between treatment and age in the MMRM analysis. The change from baseline in trough FEV1 for children aged 5-7 years was similar for all groups, including placebo (Table III) . However, in children aged 8-11 years, the change from baseline in trough FEV1 was greater than placebo for all active treatment groups (Table III) .
During the treatment period, notable differences from baseline in percentage of rescue-free days were observed for all FF groups compared with placebo. These differences were statistically significant in the FF 50 mg and FF 100 mg groups (9.8%, P = .023 and 12.2%, P = .004, respectively), and equated to an additional 0.7 and 0.9 rescue-free days per week, respectively (Table II) . For symptom-free days, small increases were observed in all groups including placebo and so statistically significant differences vs placebo were not reached in any treatment group (Table II) .
For all secondary PEF endpoints, FF treatment led to statistically significant improvements compared with placebo (except for change from baseline in evening PEF at week 12 [LOCF] for the FF 100 mg group, P = .266), although no dose ordering was observed ( Table II) . The proportion of withdrawals due to lack of efficacy over weeks 1-12 were statistically significantly lower in all FF groups (14%-19%) and the FP 100 mg group (16%) compared with placebo (35% ;  Table II ).
Other Endpoints
Improvements from baseline to week 12 were observed for both cACT score and total PAQLQ(S) score in all active treatment groups and placebo (Table II) . Adjusted treatment differences vs placebo were not statistically significant with FF for change in baseline cACT score or total PAQLQ(S) score analyses (Table II) . (20) 17 (14) 16 (13) 17 (14) 21 (18) 
Pharmacokinetics
Concentration-time data for FF from this study were merged with data from 2 previous studies in children aged 5-11 years with FF 100 mg once daily alone 14, 15 or in combination with VI. 15 The resulting population PK dataset comprised 306 children. The predicted mean FF maximum concentration (95% CI) for children in the current study was 5.7 pg/mL (5.1-6.4), 11.6 pg/mL (10.6-12.7), and 22.4 pg/mL (19.9-25.3) for the FF 25 mg, FF 50 mg, and FF 100 mg groups, respectively. The predicted mean FF AUC0-24 (95% CI) for children in the current study was 47 pg.h/mL (41-54), 98 pg.h/mL (87-110), and 196 pg.h/mL (167-230) for the FF 25 mg, FF 50 mg, and FF 100 mg groups, respectively.
Safety
The incidence of AEs was slightly greater in the FF groups (32%-36%) than in the placebo group (29%), but there was no apparent dose-ordering ( Table IV) . The most frequent AE was cough (Table IV) . Four children experienced 4 AEs considered to be related to study treatment. These were pharyngitis and cough, reported for 1 child each in the placebo group; 1 child with cough in the FF 25 mg group; and 1 child with stomatitis in the FF 100 mg group (Table IV) . Two on-treatment nonfatal serious AEs were reported; 1 event of syncope (FF 50 mg group) and 1 event of hepatitis A (FF 100 mg group) ( Table IV) . Neither was considered to be related to study treatment. Asthma exacerbations were experienced by 12 children 1%] in the FF 100 mg group). None of these children were hospitalized, but all were withdrawn from the study. Vital signs at baseline and changes from baseline at all recorded time points were similar between treatment groups.
ORIGINAL ARTICLES
In the UC population, 1 child had a 24-hour UC excretion at week 12 of 1054.4 nmol/24 hour (Figure 3 ; available at www.jpeds.com). The child had not received any additional glucocorticoids, and findings of the clinical examination of the child were unremarkable. As such, this value was considered an outlier because of technical error and not included in the primary analysis of 24-hour urinary excretion ( Figure 3 and Table V ; Table V available at www.jpeds.com). The analyses with the outlier removed were not prespecified in the protocol and are reported as post hoc analyses. Adjusted ratio to baseline values for 24-hour UC excretion were 1.07 (n = 54) for placebo, 0.95-1.00 (n = 72-75) for the FF treatment groups, and 0.96 (n = 73) for the FP group. Treatment ratios to placebo were 0.89, 0.94, and 0.90, for the FF 25 mg, FF 50 mg, and FF 100 mg groups, respectively, and there were no statistical differences between any of the FF groups and placebo.
Laboratory assessments were within the normal range at screening and week 12 except for serum carbon dioxide content values, which were below the normal range for the majority of children across all treatment groups both at baseline and at week 12 (56%-72%).
Discussion
In this study, all active treatments (FF and FP) resulted in clinically and statistically significant improvements in the mean change from baseline in morning PEF compared with placebo; however, there was no apparent dose-ordering effect in the FF treatment groups. The doses of FF used in our study were based on data from a dose-ranging study in adults and adolescents 17 and a repeat-dose study in children. 14 The lack of doseordered response was consistent with the findings of other studies that assessed lung function response to ICS both in adult patients 18 and children. 19 Although spirometry is a robust measure of lung function and can be performed in young children given encouragement and suitable conditions, in clinical practice this requires experienced specialist staff and cooperation from both the parent and child. Therefore, PEF was chosen as the primary endpoint because it is easier for children to perform than FEV1. 20 Compared with other studies of ICS in children, the treatment differences in mean change from baseline in morning PEF reported here (12.5-19.5 L/min) show a similar level of improvement. For example, in a randomized trial of FP 50 mg and FP 100 mg in children aged 4-11 years, the mean change from baseline in morning PEF ranged from 48 L/min to 51 L/min compared with 22 L/min in the placebo group (P ≤ .05). 21 Furthermore, in a randomized trial in children, the approved ICS beclomethasone dipropionate 160 mg/d resulted in a mean change from baseline in morning PEF of 30.8 L/ min compared with 9.2 L/min in the placebo group (P ≤ .01). 22 The PEF results in our study demonstrate a positive treatment effect on lung function; however, the effect on FEV1 is less clear. Although FF treatment resulted in an increase from baseline of between 150 mL and 254 mL at week 12, this was not significantly different from placebo for the 50 mg and 100 mg FF groups, mainly because of the pronounced placebo response. The increase in FEV1 vs placebo was notably greater for the FF 25 mg treatment than the other FF doses and the FP 100 mg treatment. The reason for this is unclear, but because all 3 FF doses were effective on PEF, it is possible this observation is due in part to the difficulty in obtaining good quality spirometry in children. This is supported by the post hoc analyses of FEV1 by age and acceptable FEV1 measurements.
Secondary endpoints generally supported the primary endpoint result. In particular, the assessed patient-reported outcomes suggested a favorable effect of FF treatment, with an additional 0.7 and 0.9 rescue-free days per week observed for FF 50 mg and FF 100 mg, respectively. Interestingly however, statistical significance was not reached for the change from baseline in percentage of symptom-free days over weeks 1-12. The relationship between asthma control and symptoms in children is complicated because better control often leads to an increase in physical activity. 23 A greater proportion of children withdrew from the study because of a lack of efficacy in the placebo group (35%) than in the FF groups (14%-19%) and the FP group (16%). This finding suggests that, despite the modest effects on lung function, FF was a beneficial treatment in the current study. Withdrawal rates for children receiving active treatment were similar to those observed in previous studies of children with asthma receiving ICS treatment (10%-30%). 24 In the PK analysis, a large number of FF plasma samples were below the lower limit of quantification; therefore, data from the current study were merged with historical data from FF 100 mg pediatric studies. Systemic exposure of FF over the dose range assessed was generally low and approximately dose-proportional. Peak FF plasma concentrations from the current study (22.4 pg/mL) were similar to those values estimated in children receiving FF 100 mg (24.68 pg/mL) 14 or FF/VI 100/25 mg (20.7 pg/mL). 15 The rate and extent of exposure of FF at steady state in children in the current study following FF 100 mg also was consistent with that observed in adults and adolescents (AUC(0−24) of 196 pg.h/mL compared with 181 pg.h/mL, respectively). 25 Once-daily treatment with FF was well tolerated at all doses. The overall incidence of AEs was similar across the FF treatment groups and the FP 100 mg group and was slightly greater for the FF and FP groups compared with placebo. The most common on-treatment AEs in all treatment groups (cough, nasopharyngitis, and rhinorrhea) are commonly observed in an asthmatic population. No clinically significant UC suppression was observed at week 12.
Some important features of the study include the large number of children recruited, the opportunity to assess 3 doses of FF, and the inclusion of a positive (FP) and negative (placebo) control; however, the difficulty in recruiting children with poorly controlled asthma, and in coaching good-quality spirometry THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 178 252 techniques to children, combined with the large number of withdrawals, may have contributed to the smaller-thanexpected improvement in PEF and FEV1 observed. In addition, variability in PEF measurements has been reported [26] [27] [28] and may have resulted in under-or overestimations in the detected treatment benefit in this study. Finally, it is not possible to determine whether once-daily FF is equivalent to the standard twice-daily FP. To determine this, a noninferiority study should be conducted.
All 3 doses of FF investigated in this study (25 mg, 50 mg, and 100 mg) improved the change from baseline in daily predose morning PEF in children aged 5-11 years. Notable improvements over placebo were seen for all FF treatments in the percentage of rescue-free days. All treatments were well tolerated, and no new safety concerns were identified during the study, although the overall incidence of AEs was slightly greater in active treatment groups compared with placebo. The results of this study suggest that FF is an effective treatment for children with inadequately controlled asthma. Oliver et al 
